<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347750</url>
  </required_header>
  <id_info>
    <org_study_id>001-2006.CTIL</org_study_id>
    <nct_id>NCT00347750</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Lopinavir an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <brief_summary>
    <textblock>
      The objective of this proposal is based on the assumption that the HIV infected Ethiopian&#xD;
      population responded in a different way in comparison to the Caucasian subjects to Lopinavir&#xD;
      therapy. Our preliminary data demonstrated that Ethiopian's have different Lopinavir serum&#xD;
      concentration in comparison to non-Ethiopian's. For these reasons the plan of this study is&#xD;
      to investigate the pharmacokinetic/pharmacodynamic (PK/PD) profile in both populations. The&#xD;
      results will allow to establish a better personalised medicine for HIV infected individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this proposal is based on the assumption that the HIV infected Ethiopian&#xD;
      population responded in a different way in comparison to the Caucasian subjects to Lopinavir&#xD;
      therapy. Our preliminary data demonstrated that Ethiopian's have different Lopinavir serum&#xD;
      concentration in comparison to non-Ethiopian's. For these reasons the plan of this study is&#xD;
      to investigate the pharmacokinetic/pharmacodynamic (PK/PD) profile in both populations. The&#xD;
      results will allow to establish a better personalised medicine for HIV infected individuals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of participants&#xD;
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV Infection</condition>
  <condition>AIDS</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir pharmacokinetic/pharmacodynamic analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All HIV infected Ethiopian and Non-Ethiopian subjects&#xD;
&#xD;
          -  AIDS diseased Ethiopian and Non-Ethiopian individuals&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals who are unable to sign the informed concent&#xD;
&#xD;
          -  Individuals unable to take oral medications&#xD;
&#xD;
          -  Individuals who described Lopinavir allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norberto Krivoy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>July 3, 2006</study_first_submitted>
  <study_first_submitted_qc>July 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>November 1, 2015</last_update_submitted>
  <last_update_submitted_qc>November 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <keyword>Lopinavir</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Pharmacodynamic</keyword>
  <keyword>Ethiopian population</keyword>
  <keyword>Caucasian population</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

